ProShares UltraShort NASDAQ Biotechnology
2 hedge funds and large institutions have $333K invested in ProShares UltraShort NASDAQ Biotechnology in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
50% less funds holding
Funds holding: 4 → 2 (-2)
82% less capital invested
Capital invested by funds: $1.83M → $333K (-$1.49M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.31M |
| 2 |
Jane Street
New York
|
-$214K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$3.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $310K | +$153K | +129 | +74% |
|
|
U
2
UBS
Zurich,
Switzerland
| $23K | -$3.55K | -3 | -12% |
|
|
CS
3
Credit Suisse
Zurich,
Switzerland
| – | -$1.31M | -862 | Closed |
|
|
4
Jane Street
New York
| – | -$214K | -141 | Closed |
|
BIS Hedge Fund Activity: Q3 2013 in Review
2 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2013, worth a combined $333K — down 82% from $1.83M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $153K. The largest seller was Credit Suisse, exiting entirely with an estimated $1.31M sold.
- 2 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2013, down from 4 in Q2 2013.
- Funds reported $333K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2013, down 82% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2013 and 2 closed out, a net change of -2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2013 was Susquehanna International Group, an estimated $153K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2013 was Credit Suisse, an estimated $1.31M sold.
Based on aggregated 13F filings for Q3 2013.